Replies to post #140420 on Biotech Values

[DewDiligence]

Galapagos—While this may not be a big issue in the short-term, I would think over the longer-term this is a pretty big overhang… Maybe I'm overreacting though.

I think you’re overreacting a little. ABT’s in-house JAK-1 is pretty far behind GLPG0634. Moreover, as rkrw noted in #msg-74530950, having ABT decline to exercise the option on GLPG0634 is not necessarily a bad outcome for Galapagos.

[jq1234]

ABT494 is still in pre-clinical, thus more likely a backup than to replace GLPG0634.